Market Research Logo

Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 2016

Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 2016, provides an overview of the Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline landscape.

Shigella Infections (Shigellosis) is an intestinal disease caused by bacteria known as shigella. Symptoms include diarrhea, abdominal cramps and fever. Predisposing factors include eating contaminated food, age, international travelers and homosexual men. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bacillary Dysentery (Shigellosis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacillary Dysentery (Shigellosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 4 and 2 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 3 and 1 molecules, respectively for Bacillary Dysentery (Shigellosis).

Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bacillary Dysentery (Shigellosis) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Bacillary Dysentery (Shigellosis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bacillary Dysentery (Shigellosis) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bacillary Dysentery (Shigellosis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bacillary Dysentery (Shigellosis) (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bacillary Dysentery (Shigellosis) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Bacillary Dysentery (Shigellosis) Overview
Therapeutics Development
Pipeline Products for Bacillary Dysentery (Shigellosis) - Overview
Pipeline Products for Bacillary Dysentery (Shigellosis) - Comparative Analysis
Bacillary Dysentery (Shigellosis) - Therapeutics under Development by Companies
Bacillary Dysentery (Shigellosis) - Therapeutics under Investigation by Universities/Institutes
Bacillary Dysentery (Shigellosis) - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Bacillary Dysentery (Shigellosis) - Products under Development by Companies
Bacillary Dysentery (Shigellosis) - Products under Investigation by Universities/Institutes
Bacillary Dysentery (Shigellosis) - Companies Involved in Therapeutics Development
Akthelia Pharmaceuticals Limited
GlaxoSmithKline Plc
Microbiotix, Inc.
Protein Potential, LLC
Visterra, Inc.
Bacillary Dysentery (Shigellosis) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(shigella + typhoid) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AKT-10081 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GVXNSD-133 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INX-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KKL-35 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-599 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SE-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF2a-TT15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
shigella vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
shigella vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
shigella vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
shigella vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Shigetec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIS-GMN - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bacillary Dysentery (Shigellosis) - Dormant Projects
Bacillary Dysentery (Shigellosis) - Discontinued Products
Bacillary Dysentery (Shigellosis) - Product Development Milestones
Featured News & Press Releases
Jul 29, 2013: GlycoVaxyn Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine
Feb 20, 2013: NIH-Funded Researchers Begin Trial of Shigella Vaccine Candidates
Oct 08, 2010: GlycoVaxyn Phase I Clinical Study Shows Positive Data With Shigella Dysenteriae Vaccine Candidate Against Severe Diarrheal Disease
Feb 23, 2010: GlycoVaxyn Initiates Phase I Clinical Study with Bioconjugate Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Bacillary Dysentery (Shigellosis), H2 2016
Number of Products under Development for Bacillary Dysentery (Shigellosis) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Bacillary Dysentery (Shigellosis) - Pipeline by Akthelia Pharmaceuticals Limited, H2 2016
Bacillary Dysentery (Shigellosis) - Pipeline by GlaxoSmithKline Plc, H2 2016
Bacillary Dysentery (Shigellosis) - Pipeline by Microbiotix, Inc., H2 2016
Bacillary Dysentery (Shigellosis) - Pipeline by Protein Potential, LLC, H2 2016
Bacillary Dysentery (Shigellosis) - Pipeline by Visterra, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Bacillary Dysentery (Shigellosis) - Dormant Projects, H2 2016
Bacillary Dysentery (Shigellosis) - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Bacillary Dysentery (Shigellosis), H2 2016
Number of Products under Development for Bacillary Dysentery (Shigellosis) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report